Replies to post #71 on Odyssey Health Inc (ODYY)

[midtownmurphy]

Thanks for the info Cabo. I've been a believer since it was .17 :-). $ODYY is a game changer !!!!!

[FUNMAN]

NFL legend Brett Favre invests in concussion treatment meant to cure CTE
By Angelica Stabile

Published 2 days ago

FOX Business

https://www.fox6now.com/sports/nfl-legend-brett-favre-invests-in-concussion-treatment-meant-to-cure-cte

WASHINGTON - Professional football’s concussion crisis could be turning around as NFL Hall of Famer Brett Favre has backed a promising preventative treatment for head injuries.

The former Green Bay Packers quarterback told FOX Business’ "Kennedy" on Monday he’s an investor in pharmaceutical company Prevacus, which is developing a concussion medication called Prevasol, which could be the first step to preventing CTE.

"Concussions are going to happen, regardless of how good the helmets are," Favre explained. "Spending more resources and time on prevention, rather than some type of treatment, is where [the NFL is] lacking."

Prevacus president and founder Dr. Jacob Vanlandingham joined the conversation to explain how Prevasol works. He said the treatment is to be used directly after a concussion occurs to limit long-term damage.

The drug, taken via nasal spray, reportedly helps repair nerves and promotes cell growth, and has entered phase one of human trials. Vanlandingham explained that Prevasol is considered a "neuro-steroid" that penetrates the blood-brain barrier "relatively quickly."

"We can get the drug in the brain in less than five minutes," he said. "And our plan is, when we get that diagnosis on the field of play, give the drug nasally, get it in the brain quickly."

Once the drug enters the nucleus of the brain, Vanlandingham added, it reduces swelling, inflammation and oxidative stress simultaneously. The doctor expects phase one trials to wrap up this year.

Prevacus has recently been acquired by Odyssey Group International – traded publicly under ODYY – which allowed the company financial liberty to conduct trials.

[FUNMAN]

Odyssey Group International/Prevacus, Inc. Reports Brain Bio-Distribution Findings of PRV-002

https://finance.yahoo.com/news/odyssey-group-international-prevacus-inc-130000571.html

I placed a new "buy order" this morning. - FUNMAN

Wed, February 17, 2021, 8:00 AM·4 min read

Pre-clinical data for PRV-002, a nasally delivered drug in development for treating concussion, highlight rapid brain bioavailability

IRVINE, CA / ACCESSWIRE / February 17, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) ("Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, and Prevacus Inc., are pleased to report the results of pre-clinical studies related to brain biodistribution of PRV-002 (Prevasol), a novel compound in development for the treatment of concussion.

In this study, PRV-002, a neurosteroid, was formulated in its native form and as a nanoparticle. Pre-clinical animal studies of PRV-002 have shown rapid absorption in the brain with biodistribution across the entire brain when administered nasally.

"We are pleased to see such a significant level of the compound reach the brain over the 8-hour period of nasal administration. These data confirm our hypothesis that the administration of nasal nanoparticles improves brain bioavailability. PRV-002 was most concentrated in the frontal lobe, which makes perfect sense given its direct connection with the olfactory nerves. Nasal application is ideal for quick, on-the-field administration and conditions of acute brain inflammation where immediate treatment is critical." said Dr. Jake VanLandingham, Chief Executive Officer of Prevacus.

In this study, conducted by Inotiv for Prevacus, both forms of PRV-002 were nasally administered to subjects three times: one initial dose and two subsequent doses given in 4-hour intervals. Brain tissue was analyzed at 8-hours post-initial nasal application. When formulated as a nanoparticle, approximately 40% more PRV-002 was found in all brain cortices, including the cerebellum, at 8-hours. These results were almost identical when measured in cerebrospinal fluid. When allometrically scaled, the dosing concentrations in this study represent the lowest dose intended for use in the planned Phase 1 human trials.

Michael Redmond, CEO of Odyssey added, "concussion is a serious health issue in sports, the military and in elderly populations which currently has no FDA approved drug treatment. These animal data support PRV-002's brain bioavailability following brain trauma. We are eager to close our transaction and contribute to the drug development program."

Odyssey previously entered into a definitive agreement with Prevacus to acquire the Active Pharmaceutical Ingredient PRV-002 (Prevasol) to treat traumatic brain injury on January 11, 2021. The definitive agreement has been signed, and the transaction is expected to close by the end of February 2021. The transaction is conditional on Prevacus shareholder approval and other customary closing conditions.

About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.

For more information, visit: http://www.odysseygi.com

About Prevacus, Inc.
Prevacus, Inc. is a biopharmaceutical company developing drug candidates with the potential to advance treatment in the fields of traumatic brain injury and other neurological disorders. The Company's first two development candidates (PRV-002 and PreVPro) represent breakthrough strategy for treating concussion working at the molecular level to simultaneously reduce inflammation, swelling, impaired cerebral blood flow and oxidative stress.

For more information visit: http://www.prevacus.com.

Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.

Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
[e-mail]

SOURCE: Odyssey Group International, Inc

[FUNMAN]

(See Blue) Phase 1 trial coming. (ODYY) Odyssey Group International, Inc. Closes Acquisition of Novel Concussion Drug

Tue, March 2, 2021, 8:30 AM·3 min read

Anticipates initiation of Phase 1 clinical trials of PRV-002 during the Second Quarter of 2021 - That's on the near term horizon; just 30 - 120 days. - FUNMAN

IRVINE, CA / ACCESSWIRE / March 2, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) ("Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that it has closed the previously announced acquisition of drug candidate PRV-002, a novel neurosteroid being developed for the treatment of concussion (mild traumatic brain injury (mTBI)), from Prevacus, Inc. ("Prevacus") in an all-stock transaction. A comprehensive video of the drug, and a description of how it works is available on the Company's Youtube channel.

Concussion has become an epidemic in sports, military and elderly populations. More than 3 million sports and recreational concussions occur in the U.S. annually, and an estimated 1.5 million more go unreported. These figures do not include the significant number of concussions sustained in other high-risk incidents, including motor vehicle accidents and elderly falls. Despite the high incidence rate, there are currently no FDA-approved drugs for concussion; the market for a treatment is estimated to be over $2 billion annually.

In preclinical animal studies, nasal administration of PRV-002 has shown rapid, broad brain biodistribution and simultaneously reduced swelling, inflammation and oxidative stress with positive safety data. In addition, results from subjects treated with PRV-002 post-concussion showed positive behavioral outcomes using various testing platforms.

Dr. Jake VanLandingham, Chief Executive Officer of Prevacus, has joined Odyssey as the Company's new Vice President of Drug Development and will continue to lead the development of PRV-002. Dr. VanLandingham stated, "I am honored and excited to join Odyssey. PRV-002 has performed well in preclinical studies with promising efficacy and safety data in animal models. We will be laser-focused on the initiation of our first in-human clinical trials during the second quarter of 2021."

Michael Redmond, CEO of Odyssey added, "I am thrilled to welcome Dr. VanLandingham to the Odyssey team. His drug development ability and expertise will be invaluable as we develop PRV-002 and for future projects. Concussion is a serious health issues and we believe that by developing PRV-002 we can significantly improve patient outcomes."

About Odyssey Group International, Inc.

Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.

For more information, visit: http://www.odysseygi.com

About Prevacus, Inc.

Prevacus, Inc. is a biopharmaceutical company developing drug candidates with the potential to advance treatment in the fields of traumatic brain injury and other neurological disorders. The Company's first two development candidates (PRV-002 and PreVPro) represent breakthrough strategy for treating concussion working at the molecular level to simultaneously reduce inflammation, swelling, impaired cerebral blood flow and oxidative stress.

For more information visit: http://www.prevacus.com.

Forward-Looking Statements

This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.

Media and Investors Contacts:

CG CAPITAL
Rich Cockrell
877.889.1972
[e-mail]

SOURCE: Odyssey Group International Inc.

[FUNMAN]

Odyssey Group International Announces Upcoming Television Appearance by Brett Favre and Dr. Jake VanLandingham on NewsNation Now’s “The Donlon Report”

Wed, March 10, 2021, 8:30 AM·3 min read

MGMT really knows how to keep ODYY in the news. They are promoting the PPS with "influencers". - FUNMAN

https://finance.yahoo.com/news/odyssey-group-international-announces-upcoming-133000782.html

IRVINE, CA / ACCESSWIRE / March 10, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce that Dr. Jake VanLandingham, Odyssey's Vice President of Drug Development and the lead scientist developing PRV-002 will be joining Brett Favre to discuss the impact of concussions and the importance of this novel concussion treatment on NewsNation Now's "The Donlon Report." The segment is expected to air at 7:30PM Eastern Time on March 10, 2021.

"I am pleased that PRV-002, our pre-clinical stage concussion treatment continues to receive so much attention from the media," said Dr. Jake VanLandingham. "We look forward to continuing development of the drug through the initiation of our upcoming human clinical trials."

Dr. VanLandingham has appeared alongside Brett Favre on numerous media segments to discuss the impact of concussion and the development of PRV-002 including:

CheddarTV's "Closing Bell" on Friday, February 5 (watch online)

Newsmax's "National Report" on Sunday, February 7 (watch online) and

Fox Business' "Kennedy Nation" on Monday February 8 (watch online)

In addition, former NFL stars Kurt Warner and Mark Rypien discussed PRV-002 on Fox News' "Fox and Friends" on Saturday, February 6 (watch online).

Odyssey acquired PRV-002 via an all-stock transaction that closed March 2, 2021.

About Odyssey Group International, Inc.

Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.

For more information, visit http://www.odysseygi.com.

About PRV-002

PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.

Forward-Looking Statements

This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.

Media and Investors Contacts:

CG CAPITAL
Rich Cockrell
877.889.1972
[e-mail]

SOURCE: Odyssey Group International Inc.



View source version on accesswire.com:
https://www.accesswire.com/634545/Odyssey-Group-International-Announces-Upcoming-Television-Appearance-by-Brett-Favre-and-Dr-Jake-VanLandingham-on-NewsNation-Nows-The-Donlon-Report